HER2阴性乳腺癌中雌激素/孕激素受体低表达的生存结果与三阴性乳腺癌相似。

Survival outcome of weak estrogen/progesterone receptor expression in HER2 negative breast cancer is similar to triple negative breast cancer.

作者信息

Liao G-S, Dai M-S, Hsu H-M, Chu C-H, Hong Z-J, Fu C-Y, Chou Y-C, Huang T-C, Yu J-C

机构信息

Division of General Surgery, Department of Surgery, Tri-Services General Hospital, National Defense Medical Center, Taipei, Taiwan.

Division of Hematology/Oncology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.

出版信息

Eur J Surg Oncol. 2017 Oct;43(10):1855-1861. doi: 10.1016/j.ejso.2017.07.001. Epub 2017 Jul 19.

DOI:10.1016/j.ejso.2017.07.001

PMID:28756019

Abstract

BACKGROUND

Recent publications have suggested that human epidermal growth factor receptor 2 (HER2)-negative breast cancers with "weak" estrogen receptor (ER)/progesterone receptor (PR) expression levels by immunohistochemical (IHC) analysis were considered as the triple-negative (TN) subtype. This study aimed to evaluate the overall survival (OS), disease-free survival rates (DFS), and disease-specific survival (DSS) based on ER and PR expression levels into one of three groups, ER and PR <1%, ER and PR 1%-20%, and ER or PR >20% by hormone therapy.

METHODS

Medical records of 3353 breast cancer patients treated from 2006 to 2013 were retrospectively reviewed. Tumor characteristics, type of treatment, OS, DFS and DSS were evaluated among the three patient groups.

RESULTS

Regarding OS, there were significant differences according to the received hormone therapy in the different groups: ER and PR <1% (P = 0.972), ER and PR 1%-20% (P = 0.264), and ER or PR >20% (P = 0.014). Regarding DFS and DSS, there were also significant differences in the different groups: ER and PR <1% (P = 0.611, 0.766), ER and PR 1%-20% (P = 0.847, 0.629), and ER or PR >20% (P = 0.031, 0.002).

CONCLUSIONS

In HER2 negative breast cancer patient with hormone therapy, ER and PR expression level of 1%-20% has similar survival outcome to the ER and PR expression level of <1% by IHC analysis.

摘要

背景

近期发表的研究表明，通过免疫组织化学（IHC）分析显示雌激素受体（ER）/孕激素受体（PR）表达水平“弱”的人表皮生长因子受体2（HER2）阴性乳腺癌被视为三阴性（TN）亚型。本研究旨在根据ER和PR表达水平将患者分为三组，即ER和PR<1%、ER和PR 1%-20%以及ER或PR>20%，通过激素治疗评估总生存期（OS）、无病生存率（DFS）和疾病特异性生存率（DSS）。

方法

回顾性分析了2006年至2013年接受治疗的3353例乳腺癌患者的病历。对三组患者的肿瘤特征、治疗类型、OS、DFS和DSS进行了评估。

结果

关于OS，不同组接受的激素治疗存在显著差异：ER和PR<1%（P = 0.972），ER和PR 1%-20%（P = 0.264），ER或PR>20%（P = 0.014）。关于DFS和DSS，不同组也存在显著差异：ER和PR<1%（P = 0.611，0.766），ER和PR 1%-20%（P = 0.847，0.629），ER或PR>20%（P = 0.031，0.002）。